What This Workup Supports and What It Does Not

The guided case supports a targeted FVIII workup: an isolated prolonged aPTT, a mixing study that worsens on incubation, low FVIII activity confirmed by two independent methods, and a detected Nijmegen-Bethesda titer together build a pattern consistent with an acquired FVIII inhibitor. None of these results in isolation, including the mixing study, establishes or excludes acquired hemophilia A by itself; mixing studies are poorly standardized for that purpose, and low FVIII has differentials beyond a specific inhibitor.

What is not supplied: a universal parallelism acceptance limit, mixing-study interpretation index, inhibitor positivity cutoff, or critical-value threshold. Those come from the current local validated method, manufacturer instructions for use, and the laboratory's own verified performance specifications. Managing bleeding or directing treatment is also not addressed here; that decision belongs to the treating clinician and specialist team once the laboratory has escalated an unexplained result.

A broad pattern of multiple factor deficiencies with both PT and aPTT prolonged points toward reduced hepatic synthesis or vitamin K deficiency rather than a single specific inhibitor, a reminder that the same screening abnormality can have very different explanations depending on which factors and which methods are involved.

Separate what each assay measures from what the overall pattern may mean, keep every method-specific number tied to its own local validation, and route an unexplained result to a specialist rather than closing the case on your own.